Earnings season is in full swing, and while fourth-quarter earnings are expected to be an upside catalyst for most companies, shareholders of embattled drugmaker Valeant Pharmaceuticals (NYSE:VRX) are probably terrified. Valeant, which was at one time worth around $90 billion, has shed more than 90% of its value since the summer of 2015.
